<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol J</journal-id><journal-title>Virology Journal</journal-title><issn pub-type="epub">1743-422X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19216773</article-id><article-id pub-id-type="pmc">2649057</article-id><article-id pub-id-type="publisher-id">1743-422X-6-21</article-id><article-id pub-id-type="doi">10.1186/1743-422X-6-21</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Prevalence of HBV and HCV among blood donors in Kosovo</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Fejza</surname><given-names>Hajrullah</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>drfejzah@gmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Telaku</surname><given-names>Skender</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>skendert@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Sector for Public Health, Municipality of Prishtina, Kosovo</aff><aff id="I2"><label>2</label>Gastroenterology Unit, University Clinical Center of Kosovo, Prishtina, Kosovo</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>2</month><year>2009</year></pub-date><volume>6</volume><fpage>21</fpage><lpage>21</lpage><ext-link ext-link-type="uri" xlink:href="http://www.virologyj.com/content/6/1/21"/><history><date date-type="received"><day>15</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Fejza and Telaku; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Fejza and Telaku; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>               Fejza               Hajrullah                              drfejzah@gmail.com            </dc:author><dc:title>            Prevalence of HBV and HCV among blood donors in Kosovo         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Virology Journal 6(1): 21-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1743-422X(2009)6:1&#x0003c;21&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1743-422X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Hepatitis is disease of the liver caused by the infectious and non-infectious agents.</p><p>The aim of study was to analyze the prevalence of HBV and HCV among voluntary blood donors in Kosovo, during 2000&#x02013;2003.</p><p>The data from National Center for Blood Transfusion of Kosovo were collected and analyzed through descriptive and comparative epidemiological method of retrospective study. All samples were tested by ELISA test.</p><p>Out of 70348 samples of the blood donors, 3145 were positive. From overall positive samples, 2939 were HBV positive, 192 HCV positive while 14 samples were positive for both viruses.</p><p>The HBV prevalence among the blood donors of Kosovo is 4.2%, which range Kosovo to the second zone according to the CDC classification of the geographical spread of the HBV infection.</p><p>The HCV prevalence among the blood donors in Kosovo is 0.3%. Compared to the other European countries this level of prevalence is relatively low.</p><p>Age group 30&#x02013;39 years old was presented with 34.8% of cases. The higher number was among the workers, 842 or 26.8%.</p><p>Based on the results we can conclude that Kosovo have the similar prevalence for HBV and HCV infections as other South East European countries.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Hepatitis is term to describe a nonspecific liver inflammation [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Until now are known 8 types of hepatitis: A, B, C, D, E, F, G and TT. Hepatitis B and C are similar types of liver infection, which are mostly spread through blood and blood products.</p><p>The possibility of hepatitis transmission through blood and blood products were known since 1950 [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Hepatitis B virus is an AND virus from hepadnaviridae family. Hepatitis C virus is an ARN virus with lipid coat similar to flaviviridae family.</p><p>Infected person or asymptomatic carriers with viral hepatitis B and C are only reservoir of infection [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Researches show as that world prevalence of HBsAg carriers is from 0.1% till 20% with high percentage in tropical countries [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The prevalence of anti HCV antibody is variety in different world countries with high number reported for Egypt.</p></sec><sec><title>Aim of study</title><p>The aim of a study was to analyze the prevalence of the HBsAg and anti-HCV antibodies in Kosovo during the period 2000&#x02013;2003. The possible influence of the various factors on the prevalence was analyzed too. The prevalence was compared with the data available on European and World level.</p></sec><sec><title>Material and methodology</title><p>Data from databank of the voluntary blood donors of the National Blood Bank in Pristina, as well the data from the databank of the Transfusion Centers in regional Hospitals in Peja, Gjakova, Prizren and Gjilan were used in this study. The analyzed period was from 2000 &#x02013; 2003.</p><p>The method of study was descriptive and comparative in retrospective aspect.</p><p>The T &#x02013; test and &#x003a7;<sup>2</sup>- test were used to analyze the significance of the results.</p><p>All samples were tested by ELISA test.</p></sec><sec><title>Results</title><p>The results of the study showed that from 70348 samples of the blood donated by the blood donors, 3145 were positive. From overall positive samples, 2939 were HBV positive, 192 HCV positive, while in 14 samples both viruses were discovered (Table <xref ref-type="table" rid="T1">1</xref> and Figure <xref ref-type="fig" rid="F1">1</xref>)</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Infected persons with Hepatitis B and C viruses, Kosovo 2000&#x02013;2003</bold>.</p></caption><graphic xlink:href="1743-422X-6-21-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Prevalence of HBV and HCV, Kosovo 2000&#x02013;2003, by type.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Type of Infection</td><td align="center" colspan="2">HBV</td><td align="center" colspan="2">HCV</td><td align="center" colspan="2">Total</td></tr><tr><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center">N</td><td align="center">%</td><td align="center">N</td><td align="center">%</td><td align="center">N</td><td align="center">%</td></tr></thead><tbody><tr><td align="left">Mono-infection</td><td align="center">2939</td><td align="center">99.5</td><td align="center">192</td><td align="center">93.2</td><td align="center"><bold>3131</bold></td><td align="center"><bold>99.6</bold></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">Bi-infection</td><td align="center">14</td><td align="center">0.5</td><td align="center">14</td><td align="center">6.8</td><td align="center"><bold>14</bold></td><td align="center"><bold>0.4</bold></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">Total</td><td align="center">2953</td><td align="center">100.0</td><td align="center">206</td><td align="center">100.0</td><td align="center">3145</td><td align="center">100.0</td></tr></tbody></table></table-wrap><p>Male sex is represented with higher number of infected persons with HBV and HCV. From overall infected persons, 90.3% are male and only 9.7% are female. The same values are shown in infection with HBV whereas a little grow is shown in infection with HCV where female sex is represented with 14.6% (Figure <xref ref-type="fig" rid="F2">2</xref>)</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Infection with HBV and HCV among blood donors in Kosovo, 2000&#x02013;2003 By type and sex</bold>.</p></caption><graphic xlink:href="1743-422X-6-21-2"/></fig><p>The most of infected persons with HBV and HCV belongs to age group from 20&#x02013;29 years and from 30&#x02013;39 years.</p><p>Higher number is registered in age group from 30&#x02013;39 years with value of 34.8%, whereas age group from 20&#x02013;29 years is represented with 33.3%. The less value is shown in age group over 50 year with 4.9%. The average of infected persons is 32.2 year with SD 9.4 (Table <xref ref-type="table" rid="T2">2</xref>)</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Infection with HBV and HCV among blood donors in Kosovo, by age group and years.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="4">Year</td><td align="center" colspan="2">Total</td></tr></thead><tbody><tr><td align="left">Age group</td><td align="center">2000</td><td align="center">2001</td><td align="center">2002</td><td align="center">2003</td><td align="center">N</td><td align="center">%</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">10&#x02013;19</td><td align="center">32</td><td align="center">52</td><td align="center">126</td><td align="center">77</td><td align="center">287</td><td align="center">9.1</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">20&#x02013;29</td><td align="center">260</td><td align="center">256</td><td align="center">322</td><td align="center">209</td><td align="center">1047</td><td align="center">33.3</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">30&#x02013;39</td><td align="center">262</td><td align="center">294</td><td align="center">308</td><td align="center">232</td><td align="center"><bold>1096</bold></td><td align="center"><bold>34.8</bold></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">40&#x02013;49</td><td align="center">137</td><td align="center">113</td><td align="center">170</td><td align="center">140</td><td align="center">560</td><td align="center">17.8</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">50+</td><td align="center">44</td><td align="center">25</td><td align="center">59</td><td align="center">27</td><td align="center">155</td><td align="center">4.9</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">Total</td><td align="center">735</td><td align="center">740</td><td align="center">985</td><td align="center">685</td><td align="center">3145</td><td align="center">100.0</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">Average</td><td align="center">33.3</td><td align="center">32.0</td><td align="center">31.7</td><td align="center">32.0</td><td align="center"><bold>32.2</bold></td><td align="center">-</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left">SD</td><td align="center">9.3</td><td align="center">8.8</td><td align="center">10.0</td><td align="center">9.4</td><td align="center"><bold>9.4</bold></td><td align="center">-</td></tr></tbody></table></table-wrap><p>The blood donors which samples were analyzed belong to different occupations. However, the highest number, 842 (26.8%) were workers, followed by pupils with 7.3%. The lowest number was among traders, 3.1%, (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Infection with HBV and HCV among blood donors in Kosovo, 2000&#x02013;2003 By occupation and years</bold>.</p></caption><graphic xlink:href="1743-422X-6-21-3"/></fig></sec><sec><title>Discussion</title><p>Infection with HBV and HCV are worldwide significant problem in public health [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. About 5% (300 millions), of world population has chronic infection HBV, which is major factor for developing of chronic liver cirrhosis and carcinoma hepatocelulare [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B23">23</xref>].</p><p>According to CDC estimation about 3.9 million people worldwide are infected with HCV, with highest prevalence among age group 30&#x02013;39 year and about 8000&#x02013;10 000 death/year from lives disease caused from HCV infection, (CDC, 1998).</p><p>The prevalence of HCV in world level can be more than 3%, [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B27">27</xref>].</p><p>Out of 70348 samples of the blood donors, 3145 were positive. From overall positive samples, 2939 were HBV positive, 192 HCV positive while 14 samples were positive for both viruses.</p><p>The HBV prevalence among the blood donors of Kosovo is 4.2%, which range Kosovo to the second zone according to the CDC classification of the geographical spread of the HBV infection.</p><p>According to the study done in 1992 among blood donors in Kosovo, the prevalence of HBV was 12, 05%, [<xref ref-type="bibr" rid="B21">21</xref>]. We can conclude that after the adequate preventives measures in this period, the prevalence of HBV is decreased significantly.</p><p>The prevalence of HBV in dialyses patients in Kosovo is 24.2%, [<xref ref-type="bibr" rid="B28">28</xref>]. We think that such highest prevalence is caused because of continually percutane blood exposure.</p><p>The HCV prevalence among the blood donors in Kosovo is 0.3%. Compared to the other European countries this level of prevalence is relatively low.</p><p>According to the WHO, the world prevalence with HCV is 3.1% [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. The highest prevalence is in Africa, 5.3%, whereas the lowest prevalence is in Europe, 1.03%, [<xref ref-type="bibr" rid="B30">30</xref>]. The highest prevalence of HCV between countries in whole the world is in Egypt, 6&#x02013;28% (mean 22%), [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>].</p><p>We can conclude that lower prevalence of HCV in Kosovo is because here are not a lot of people living in high-risk groups for infection with HCV.</p><p>The prevalence of HCV among dialyses patients in Kosovo is 38.8%, [<xref ref-type="bibr" rid="B28">28</xref>]. This finding can confirm the meaning that long exposure to blood and blood products is with high risk for infection with HCV.</p><p>Age group 30&#x02013;39 years old was presented with 34.8% of cases. The higher number was among the workers, 842 or 26.8%.</p></sec><sec><title>Conclusion</title><p>&#x02022; Prevalence of HBV among blood donors in Kosovo is 4.2%.</p><p>&#x02022; Prevalence of HCV among blood donors in Kosovo is 0.3%.</p><p>&#x02022; Based on the results we can conclude that we have the similar prevalence for HBV and HCV infections as other southeast European countries.</p></sec><sec><title>Proposition of measures</title><p>&#x02022; To ensure health education activities among population regarding those infections,</p><p>&#x02022; To effort programs and projects which mean the activities with risk group population insisting of them to use condoms and another protection measures during sexual activities and professional care.</p><p>&#x02022; To find sources for completing the lab with best tests such are RIBA and PCR.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>HF carried about data collecting, participated in design of the study and drafted manuscript. ST participated in design of the study and performed the statistical analysis. Both authors read and approved the final manuscript.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>MJ</given-names></name><name><surname>Kruszon-Moran</surname><given-names>D</given-names></name><name><surname>Nainan</surname><given-names>OV</given-names></name><name><surname>McQuillan</surname><given-names>GM</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Moyer</surname><given-names>LA</given-names></name><name><surname>Kaslow</surname><given-names>RA</given-names></name><name><surname>Margolis</surname><given-names>HS</given-names></name></person-group><article-title>The prevalence of hepatitis C virus infection in the US, 1988 through 1994</article-title><source>N England J Med</source><year>1999</year><volume>341</volume><fpage>556</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10451460</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199908193410802</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>JC</given-names></name><name><surname>O'Grady</surname><given-names>J</given-names></name><name><surname>Neuberger</surname><given-names>J</given-names></name></person-group><article-title>Clinical guidelines on the management of hepatitis C</article-title><source>Gut</source><year>2001</year><volume>49</volume><comment>I-I-21</comment><pub-id pub-id-type="pmid">11413125</pub-id></citation></ref><ref id="B3"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gerstman</surname><given-names>B</given-names></name></person-group><source>Epidemiology &#x02013; kept simple</source><year>2003</year><volume>Chapter 6, 9, 12, 13 &#x00026; 20</volume><edition>Second</edition><publisher-name>Wiley-Liss, New Jersy</publisher-name></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><collab>CDC</collab></person-group><article-title>Updates U.S Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Post exposure Prophylaxis</article-title><source>MMWR</source><year>2001</year><volume>50</volume></citation></ref><ref id="B5"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Friss</surname><given-names>R</given-names></name><name><surname>Seller</surname><given-names>ThA</given-names></name></person-group><source>Epidemiology for public health practice</source><year>2004</year><volume>Chapter 12</volume><publisher-name>Jones and Bartlett Publishers, London</publisher-name></citation></ref><ref id="B6"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hillyer</surname><given-names>CD</given-names></name><name><surname>Hillyer</surname><given-names>KL</given-names></name><name><surname>Strobe</surname><given-names>FJ</given-names></name><name><surname>Jeffries</surname><given-names>LC</given-names></name><name><surname>Siberstein</surname><given-names>LE</given-names></name></person-group><source>Handbook of Transfusion Medicine</source><year>2001</year><volume>Chapter 2 and 32</volume><publisher-name>Academic Press, London</publisher-name></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerny</surname><given-names>A</given-names></name><name><surname>Chisari</surname><given-names>FV</given-names></name></person-group><article-title>Pathogenesis of chronic hepatitis C: immunology features of hepatic injury and viral persistence</article-title><source>Hepatology</source><year>1999</year><volume>30</volume><fpage>595</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">10462362</pub-id><pub-id pub-id-type="doi">10.1002/hep.510300312</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>FJ</given-names></name></person-group><article-title>Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection Clinical Microbiology Review</article-title><year>1999</year><volume>12</volume><fpage>351</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">10194463 </pub-id></citation></ref><ref id="B9"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Harmening</surname><given-names>DM</given-names></name></person-group><article-title>Modern blood banking and Transfusion Practices</article-title><source>Philadelphia, USA</source><year>1999</year><volume>25</volume><edition>IV</edition><fpage>1231</fpage><lpage>1243</lpage></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>P</given-names></name><name><surname>Charles</surname><given-names>G</given-names></name><name><surname>David</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>JA</given-names></name></person-group><article-title>Oxford handbook of public health practice</article-title><source>Oxford</source><year>2004</year><volume>Chapter 1.2</volume></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebeling</surname><given-names>F</given-names></name></person-group><article-title>Epidemiology of the Hepatitis C virus</article-title><source>Vox Sang</source><year>1998</year><volume>74</volume><fpage>143</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">9704437</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kyi</surname><given-names>KP</given-names></name><name><surname>Aye</surname><given-names>M</given-names></name><name><surname>Oo</surname><given-names>KM</given-names></name><name><surname>Htun</surname><given-names>Moh Moh</given-names></name><name><surname>Oo</surname><given-names>SS</given-names></name><name><surname>Lwin</surname><given-names>KO</given-names></name><name><surname>Win</surname><given-names>KM</given-names></name></person-group><article-title>Prevalence of Hepatitis C in Healthy Population and Patients with Liver Ailments in Myanmar</article-title><source>Regional Health Forum WHO South-East Asia Region</source><year>2002</year><volume>6</volume></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaller</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>KE</given-names></name><name><surname>Aladashvili</surname><given-names>M</given-names></name><name><surname>Badridze</surname><given-names>N</given-names></name><name><surname>del Rio</surname><given-names>C</given-names></name><name><surname>Tsertvadze</surname><given-names>T</given-names></name></person-group><article-title>Risk factors for Hepatitis C virus infection among blood donors in Georgia</article-title><source>European Journal of Epidemiology, Netherlands</source><year>2004</year><volume>19</volume><fpage>547</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1023/B:EJEP.0000032352.29173.78</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name></person-group><article-title>Hepatitis C virus infection</article-title><source>N England J Med</source><year>2001</year><volume>345</volume><fpage>45</fpage><lpage>52</lpage></citation></ref><ref id="B15"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>K</given-names></name><name><surname>Wiliams</surname><given-names>CM</given-names></name><name><surname>Graham</surname><given-names>NMH</given-names></name></person-group><source>Infectious Disease Epidemiology</source><year>2004</year><volume>Chapter 19</volume><publisher-name>Jones and Bartlett Publishers, London</publisher-name></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimka</surname><given-names>N</given-names></name><name><surname>Kingsley</surname><given-names>LA</given-names></name><name><surname>Sayah</surname><given-names>N</given-names></name><name><surname>Rinaldo</surname><given-names>CR</given-names></name></person-group><article-title>Hepatitis C virus infection in a male homosexual cohort: risk factor analysis</article-title><source>Genitourin Med</source><year>1996</year><volume>72</volume><fpage>213</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">8707327</pub-id></citation></ref><ref id="B17"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gordis</surname><given-names>L</given-names></name></person-group><source>Epidemiology</source><year>2004</year><edition>Third</edition><publisher-name>Elsevier Inc.(USA)</publisher-name></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>ASF</given-names></name></person-group><article-title>Chronic hepatitis B</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>1682</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12037146</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200205303462202</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dienstag</surname><given-names>JL</given-names></name><name><surname>Schiff</surname><given-names>ER</given-names></name><name><surname>Wright</surname><given-names>TL</given-names></name><name><surname>Perrillo</surname><given-names>RP</given-names></name><name><surname>Hann</surname><given-names>H-WL</given-names></name><name><surname>Goodman</surname><given-names>Z</given-names></name><name><surname>Crowther</surname><given-names>L</given-names></name><name><surname>Condreay</surname><given-names>LD</given-names></name><name><surname>Woessner</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>NA</given-names></name><collab>for The U.S. Lamivudine Investigator Group</collab></person-group><article-title>Lamivudine as initial treatment for chronic hepatitis B in the United States</article-title><source>N England J Med</source><year>1999</year><volume>341</volume><fpage>1256</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">10528035</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199910213411702</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mailliard</surname><given-names>ME</given-names></name><name><surname>Gollan</surname><given-names>JL</given-names></name></person-group><article-title>Suppressing hepatitis B without resistance &#x02013; So far, so good</article-title><source>England J Med</source><year>2003</year><volume>348</volume><fpage>848</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1056/NEJMe020185</pub-id></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ramadani</surname><given-names>N</given-names></name></person-group><article-title>Karakteristikat epidemiologjike dhe serologjike t&#x000eb; Hepatitit B n&#x000eb; Kosov&#x000eb;</article-title><source>PhD thesis</source><year>1992</year><publisher-name>Universitety of Prishtina, Kosovo</publisher-name></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scotionitis</surname><given-names>I</given-names></name><name><surname>Brass</surname><given-names>CA</given-names></name><name><surname>Mallet</surname><given-names>PF</given-names></name></person-group><article-title>Hepatitis C: Diagnosis and Treatment</article-title><source>J Gen Intern Med</source><year>1995</year><volume>10</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">7542329</pub-id><pub-id pub-id-type="doi">10.1007/BF02599887</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>S</given-names></name></person-group><article-title>Epidemiology of hepatitis B</article-title><source>The pediatric Infectious Disease Journal</source><year>1999</year><volume>12</volume><fpage>433</fpage><lpage>436</lpage></citation></ref><ref id="B24"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Carrasco</surname><given-names>DA</given-names></name><name><surname>Newman</surname><given-names>C</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name></person-group><article-title>Treatment of viral hepatitis</article-title><source>Harrison's Principles of Internal Medicine</source><year>1998</year><volume>2</volume><edition>14</edition><fpage>1677</fpage><lpage>92</lpage></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoofnagle</surname><given-names>JH</given-names></name></person-group><article-title>Therapy for acute hepatitis C</article-title><source>N England J Med</source><year>2001</year><volume>345</volume><fpage>1495</fpage><lpage>1497</lpage><pub-id pub-id-type="pmid">11794202</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200111153452013</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>MW</given-names></name><name><surname>Shiffman</surname><given-names>ML</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Marinos</surname><given-names>G</given-names></name><name><surname>Gon&#x000e7;ales</surname><given-names>FL</given-names><suffix>Jr</suffix></name><name><surname>H&#x000e4;ussinger</surname><given-names>D</given-names></name><name><surname>Diago</surname><given-names>M</given-names></name><name><surname>Carosi</surname><given-names>G</given-names></name><name><surname>Dhumeaux</surname><given-names>D</given-names></name><name><surname>Craxi</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title><source>N England J Med</source><year>2002</year><volume>347</volume><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">12324553</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa020047</pub-id></citation></ref><ref id="B27"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Greenberger</surname><given-names>NJ</given-names></name></person-group><article-title>Hepatitis C: More Common than suspected</article-title><source>Clinical focus</source><year>1995</year><fpage>18</fpage><lpage>24</lpage></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Telaku</surname><given-names>S</given-names></name><name><surname>Zekaj</surname><given-names>S</given-names></name><name><surname>Avdijaj</surname><given-names>Xh</given-names></name><name><surname>Elezi</surname><given-names>Y</given-names></name><name><surname>Kuqi</surname><given-names>Xh</given-names></name><name><surname>Zylfiu</surname><given-names>B</given-names></name><name><surname>Rudhani</surname><given-names>I</given-names></name><name><surname>Hasanxhekaj</surname><given-names>V</given-names></name><name><surname>Fejza</surname><given-names>H</given-names></name></person-group><article-title>Prevalence of hepatitis B and C infection in dialysis patient in Kosova</article-title><source>The Turkish Journal of Gastroenterology</source><year>2003</year><volume>14</volume></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdelaal</surname><given-names>M</given-names></name><name><surname>Rowbottom</surname><given-names>D</given-names></name><name><surname>Zawawi</surname><given-names>T</given-names></name><name><surname>Scott</surname><given-names>T</given-names></name><name><surname>Gilpin</surname><given-names>C</given-names></name></person-group><article-title>Epidemiology of hepatitis C virus</article-title><source>Transfusion</source><year>1994</year><volume>34</volume><fpage>135</fpage><pub-id pub-id-type="pmid">8310483</pub-id><pub-id pub-id-type="doi">10.1046/j.1537-2995.1994.34294143941.x</pub-id></citation></ref><ref id="B30"><citation citation-type="other"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Hepatitis C global prevalence</article-title><source>Weekly Epidemiological Record</source><year>1999</year><ext-link ext-link-type="uri" xlink:href="http://www.who.int/docstore/wer/pdf/1999/wer7449.pdf"/></citation></ref><ref id="B31"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kosgeroglu</surname><given-names>N</given-names></name><name><surname>Ayranci</surname><given-names>U</given-names></name><name><surname>Vardareli</surname><given-names>E</given-names></name><name><surname>Dincer</surname><given-names>S</given-names></name></person-group><article-title>Occupational exposure to hepatitis infection among Turkish nurse</article-title><source>Epidemiology &#x00026; Infection</source><year>2004</year><volume>132</volume><publisher-name>Cambridge University Press</publisher-name><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">14979586</pub-id><pub-id pub-id-type="doi">10.1017/S0950268803001407</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>TJ</given-names></name><name><surname>Rehermann</surname><given-names>B</given-names></name><name><surname>Seeff</surname><given-names>LB</given-names></name><name><surname>Hoofnagle</surname><given-names>JH</given-names></name></person-group><article-title>Pathogenesis, natural history, treatment and prevention of hepatitis C</article-title><source>Ann Intern Med</source><year>2000</year><volume>132</volume><fpage>296</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">10681285</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names/></name><name><surname>Myers</surname><given-names>G</given-names></name><name><surname>Howard</surname><given-names>C</given-names></name><name><surname>Brettin</surname><given-names>T</given-names></name><name><surname>Bukh</surname><given-names>J</given-names></name><name><surname>Gaschen</surname><given-names>B</given-names></name><name><surname>Gojobori</surname><given-names>T</given-names></name><name><surname>Maertens</surname><given-names>G</given-names></name><name><surname>Mizokami</surname><given-names>M</given-names></name><name><surname>Nainan</surname><given-names>O</given-names></name><name><surname>Netesov</surname><given-names>S</given-names></name><name><surname>Nishioka</surname><given-names>K</given-names></name><name><surname>Shin-i</surname><given-names>T</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Stuyver</surname><given-names>L</given-names></name><name><surname>Weiner</surname><given-names>A</given-names></name></person-group><article-title>Classification, nomenclature and database development for hepatitis C virus (HCV) and related viruses. Proposal for standardization</article-title><source>Arch Virol</source><year>1998</year><volume>143</volume><fpage>249</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">9541611</pub-id><pub-id pub-id-type="doi">10.1007/s007050050479</pub-id></citation></ref></ref-list></back></article>